The IMpassion130 trial clearly demonstrated that atezolizumab plus nab-paclitaxel significantly prolonged progression-free survival in advanced or metastatic PD-L1-positive TNBC patients [11]; the study defined PD-L1-positivity as PD-L1-expressing ICs ≥1% in the tumor area [11], which is the same definition used in this study. Here, CD274 is linked to neoplasm.